N-(2-甲基丙基)己烷-1-胺 | 78579-56-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-(2-甲基丙基)己烷-1-胺
• 英文名称: N-isobutylhexane-1-amine
• 英文别名: Isobutylhexylamine；1-Hexanamine, N-(2-methylpropyl)-；N-(2-methylpropyl)hexan-1-amine
• CAS: 78579-56-3
• 化学式: C₁₀H₂₃N
• mdl: MFCD11161689
• 分子量: 157.299
• InChiKey: DSAAXQPDQLWTNC-UHFFFAOYSA-N

物化性质

• 沸点：
  194.6±8.0 °C(Predicted)
• 密度：
  0.775±0.06 g/cm3(Predicted)
• 保留指数：
  1095

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  11
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  Hexyl-phosphorimidic acid triethyl ester 在 sodium tetrahydroborate 作用下， 以 甲醇 、 苯 为溶剂， 反应 27.0h， 生成 N-(2-甲基丙基)己烷-1-胺
  参考文献：
  名称：

  A Convergent One-Pot Synthesis of Secondary Amines via Aza-Wittig Reaction

  摘要：

  Secondary amines are obtained in moderate-good yields by reduction of crude imines prepared from N-alkyltriethoxyiminophosphoranes and aldehydes via the aza-Wittig reaction. N-Alkyltriethoxyiminophosphoranes are synthesized by one-pot azidation of alkyl bromides followed by Staudinger reaction.

  DOI：

  10.1080/00397919208021323

文献信息

• IRAK DEGRADERS AND USES THEREOF
  申请人：Kymera Therapeutics, Inc.

  公开号：US20190192668A1

  公开（公告）日：2019-06-27

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。
• 12-EPI PLEUROMUTILINS
  申请人：NABRIVA THERAPEUTICS AG

  公开号：US20160332963A1

  公开（公告）日：2016-11-17

  A compound selected from 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-sulfanyl)-acetyl]-12-epi-mutilins, or 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-oxy)-acetyl]-12-epi-mutilins, wherein 12-epi-mutilin is characterized in that the mutilin ring at position 12 is substituted by two substituents, the first substituent at position 12 of the mutilin ring is a methyl group which methyl group has the inverse stereochemistry compared with the stereochemistry of the methyl group at position 12 of the naturally occurring pleuromutilin ring, the second substituent at position 12 of the mutilin ring is a hydrocarbon group comprising at least one nitrogen atom and all other substituents of the mutilin ring having the same stereochemistry compared with the stereochemistry of the substituents at the corresponding positions in the naturally occurring pleuromutilin ring; optionally in the form of a salt and/or solvate, wherein the naturally occurring pleuromutilin is of formula processes for the preparation of such compounds and their use as pharmaceuticals.

  从14-O-[((烷基、环烷基、杂环烷基、杂环芳基或芳基)-硫基)-乙酰基]-12-epi-木替林，或14-O-[((烷基、环烷基、杂环烷基、杂环芳基或芳基)-氧基)-乙酰基]-12-epi-木替林中选择的一种化合物，其中12-epi-木替林的特征在于木替林环在位置12被两个取代基取代，木替林环在位置12的第一个取代基是一个甲基基团，该甲基基团的立体化学与天然存在的普鲁木替林环在位置12的甲基基团的立体化学相反，木替林环在位置12的第二个取代基是一个含有至少一个氮原子的碳氢基团，木替林环的所有其他取代基与天然存在的普鲁木替林环中相应位置的取代基的立体化学相同；可选地以盐和/或溶剂的形式存在，其中天然存在的普鲁木替林的化学式为 制备这类化合物的方法以及它们作为药物的用途。
• PLATINUM COMPOUND HAVING AMINO OR ALKYLAMINO-CONTAINING SUCCINIC ACID DERIVATIVES AS LEAVING GROUP, PREPARTION METHOD THEREOF, AND USE THEREOF
  申请人：BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD.

  公开号：US20140349985A1

  公开（公告）日：2014-11-27

  Disclosed are a category of platinum compounds having amino- or alkylamino-containing succinato derivatives as leaving group, or pharmaceutically acceptable salts thereof, preparation method thereof, and medicinal compositions containing the compounds. Also disclosed is a use of the compounds in treating cell proliferative diseases, especially cancers. The platinum compounds of the present invention have high water solubility and small toxic side effect.

  本发明揭示了一类铂化合物，其具有氨基或烷基氨基含有琥珀酸酯衍生物作为脱离基团，或其药用可接受的盐，以及其制备方法，以及含有这些化合物的药物组合物。本发明还揭示了这些化合物在治疗细胞增殖性疾病，特别是癌症方面的用途。本发明的铂化合物具有高水溶性和小毒副作用。
• [EN] ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS<br/>[FR] COMPOSÉS ANTIVIRAUX POUR LE TRAITEMENT D'INFECTIONS À CORONAVIRUS, PICORNAVIRUS ET NOROVIRUS
  申请人：ALIGOS THERAPEUTICS INC

  公开号：WO2021252491A1

  公开（公告）日：2021-12-16

  Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating coronavirus, Picomavirus and Norovims infections with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

  本文提供了式（I）的化合物或其药用盐，包括包含本文描述的化合物（包括本文描述的化合物的药用盐）的药物组合物以及合成这些化合物的方法。本文还提供了使用式（I）的化合物或其药用盐治疗冠状病毒、皮科病毒和诺如病毒感染的方法。
• Colloidal and Nanosized Catalysts in Organic Synthesis: XXIII. Reductive Amination of Carbonyl Compounds Catalyzed by Nickel Nanoparticles in a Plug-Flow Reactor
  作者：V. M. Mokhov、Yu. V. Popov、A. N. Paputina、D. N. Nebykov、E. V. Shishkin

  DOI：10.1134/s1070363219120016

  日期：2019.12

  Reductive amination of aldehydes and ketones with primary and secondary amines under catalysis with nickel nanoparticles supported on zeolite X, MgO, or activated carbon in the gas phase or in the gas-liquid system in a plug-flow reactor proceeds at atmospheric pressure of hydrogen with the formation of secondary or tertiary amines in high yield.

  在活塞流式反应器中，在气相或气液系统中，负载在沸石X，MgO或活性炭上的镍纳米粒子在催化下，用伯胺和仲胺对醛和酮进行还原性胺化反应，在氢气的大气压下进行。高产率地形成仲胺或叔胺。